Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 92Neoplasm Metastasis 10Neoplasms 9Breast Diseases 4Advanced Breast Cancer 3Recurrence 2Neoplasms by Site 2Carcinoma, Renal Cell 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Diseases 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Post Menopausal Women With Early Breast Cancer 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Multiple Endocrine Neoplasia Type 1 1Mammary Neoplasms, Animal 1Lymphoma 1Lung Neoplasms 1Lung Diseases 1Lethal Congenital Contracture Syndrome 2 1Kidney Neoplasms 1Invasive Early Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1

Interventions

Everolimus 15surufatinib 7lutetium Lu 177 dotatate 6lanreotide 6amino-acid, glucose, and electrolyte solution 5Octreotide 5Sunitinib 4Data Collection 4pasireotide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2pembrolizumab 2fosbretabulin 2arginyllysine 2Temozolomide 2Paclitaxel 2PM 01183 2Irinotecan 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1pelcitoclax 1liposomal doxorubicin 1gadoteridol 1gadoterate meglumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroendocrine Tumors × exemestane × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡